Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma

PR-104 is a clinical stage bioreductive prodrug that is converted in vivo to its cognate alcohol, PR-104A. This dinitrobenzamide mustard is reduced to activated DNA cross-linking metabolites (hydroxylamine PR-104H and amine PR-104M) under hypoxia by one-electron reductases and independently of hypox...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Abbattista, Maria R, Jamieson, Stephen M F, Gu, Yongchuan, Nickel, Jennifer E, Pullen, Susan M, Patterson, Adam V, Wilson, William R, Guise, Christopher P
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622463/
https://ncbi.nlm.nih.gov/pubmed/25869917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1017171
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados